Overview
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
Status:
Recruiting
Recruiting
Trial end date:
2022-04-01
2022-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Global Blood Therapeutics
Criteria
Inclusion Criteria:- Healthy males and females ≥ 18 to ≤ 55 years of age
- Body mass index ≥ 18.0 to ≤ 30.0 kg/m2
- Body weight ≥ 50 kg at screening and Day -1
Exclusion Criteria:
- Positive pregnancy test or currently breastfeeding.